Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19

…, B Patel, SL Fenno, N Avula, NV Reddy… - … England Journal of …, 2022 - Mass Medical Soc
Background Early treatment to prevent severe coronavirus disease 2019 (Covid-19) is an
important component of the comprehensive response to the severe acute respiratory …

[HTML][HTML] Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind …

…, MF Pullen, V Rao, NV Reddy, N Reddy… - The Lancet Infectious …, 2023 - thelancet.com
Background Post-COVID-19 condition (also known as long COVID) is an emerging chronic
illness potentially affecting millions of people. We aimed to evaluate whether outpatient …

[HTML][HTML] Metformin reduces sars-cov-2 in a phase 3 randomized placebo controlled clinical trial

…, AA Hagen, B Patel, SL Fenno, N Avula, NV Reddy… - medRxiv, 2023 - ncbi.nlm.nih.gov
Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot
be used with many medications, and are limited to virus-specific targets. 1–3 Biophysical …

Favorable Antiviral Effect of Metformin on Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of …

…, B Patel, SL Fenno, N Avula, NV Reddy… - Clinical Infectious …, 2024 - academic.oup.com
Background Metformin has antiviral activity against RNA viruses including severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression …

Impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and booster on coronavirus disease 2019 (COVID-19) symptom severity over …

…, B Patel, SL Fenno, N Avula, NV Reddy… - Clinical Infectious …, 2023 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination
has decreasing protection from acquiring any infection with emergence of new variants; …

[HTML][HTML] Impact of SARS-CoV-2 vaccination and booster on COVID-19 symptom severity over time in the COVID-OUT trial

…, B Patel, SL Fenno, N Avula, NV Reddy… - … Diseases: An Official …, 2022 - ncbi.nlm.nih.gov
… David R Boulware, MD, MPH, corresponding author Thomas A Murray, PhD, Jennifer L
Proper, BS, Christopher J Tignanelli, MD, MS, FACS, FAMIA, John B Buse, MD, PhD, David M …

Autonomous sensory meridian response: Your patients already know, do you?

NV Reddy, AB Mohabbat - Cleveland clinic journal of medicine, 2020 - europepmc.org
Public interest in autonomous sensory meridian response (ASMR) is growing on digital media
platforms. Some people can elicit the response by watching videos containing triggering …

Strategies used for the COVID-OUT decentralized trial of outpatient treatment of SARS-CoV-2

…, KM Hartman, B Patel, SL Fenno, NV Reddy… - Journal of Clinical and …, 2023 - cambridge.org
The COVID-19 pandemic accelerated the development of decentralized clinical trials (DCT).
DCT’s are an important and pragmatic method for assessing health outcomes yet comprise …

Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection? A population-level view in the EHR-based RECOVER program

NV Reddy, HC Yeh, JS Tronieri, T Stürmer… - Journal of Clinical and …, 2023 - cambridge.org
Long-term sequelae of severe acute respiratory coronavirus-2 (SARS-CoV-2) infection may
include increased incidence of diabetes. Here we describe the temporal relationship …

Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial (preprint)

…, AA Hagan, B Patel, SL Fenno, N Avula, NV Reddy… - 2023 - pesquisa.bvsalud.org
Current antiviral treatment options for SARS-CoV-2 infections are not available globally, cannot
be used with many medications, and are limited to virus-specific targets. 1-3 Biophysical …